Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Cancer Res. 2011 Mar 15;71(6):2360–2370. doi: 10.1158/0008-5472.CAN-10-1933

Figure 2. EZH2-mediated induction of abnormal mitosis and Aurora kinase activity.

Figure 2

A and B. Immunofluorescence analysis of mitotic MCF10A- pLVX-EZH2 cells untreated or treated with Dox for 3 days (A), and in CAL51/KD and controls (B). p-H3 marks mitotic DNA; Aurora A marks the centrosomes. Bar graphs show the percentage of cells with > 2 centrosomes ± SD. The number of mitotic cells per 300 cells was 59 (19%) and 78 (26%) for untreated and Dox treated cells, respectively. The number of mitotic cells per 300 cells was 198 (66%) and 78 (26%) for control and EZH2 KD cells, respectively. C. Western blot analysis of MCF10A-pLVX-EZH2 cells untreated or treated with Nocodazole (50 ng/ml for 20 h at 80% confluence) to induce mitotic arrest. EZH2 overexpression induces Aurora A and B levels in asynchronized cultures, and upregulates p Aurora A and B, p Plk1, and the Aurora kinase substrate p H3 Ser10 in Nocodazole treated cells. D. Western blot of CAL51 cells untreated or treated with Nocodazole. EZH2 KD in CAL51 cells show the opposite effects than EZH2 overexpression.

HHS Vulnerability Disclosure